Retatrutide and trizepatide are a novel class of medications that bind to both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These dual receptor agonists exhibit significant therapeutic efficacy in the control of type 2 diabetes. Retatrutide, a once-weekly subcutaneous injection, engages both